Sino Biopharmaceutical Limited
1177
Classement en actions
#1795
Sino Biopharmaceutical Limited, an investment holding company, operates as a... Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand, and colistimethate sodium for injection under Tianyun brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anhengji. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH2722; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD303, a ropivacaine sustained-release solution. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
Prix de l'action
$0.67161271
Dernière synchronisation: 2026-10-16
Capitalisation boursière
$11.96B
Changement (1 jour)
-0.38%
Changement (1 an)
-28.30%
Pays
HK
Échange Sino Biopharmaceutical Limited (1177)
Catégorie
Healthcare
Marge opérationnelle de Sino Biopharmaceutical Limited (1177)
Marge opérationnelle au October 2026 TTM : 29.76%
Selon les derniers rapports financiers et le cours de l'action de Sino Biopharmaceutical Limited, la marge opérationnelle actuelle (TTM) est de 29.76%. À la fin de 2023, elle était de 22.08%.
Historique de la marge opérationnelle pour Sino Biopharmaceutical Limited de 2000 à 2026
Marge opérationnelle à la fin de chaque année
| Année | Marge opérationnelle | Changez |
|---|---|---|
| 2026 (TTM) | 29.76% | 39.98% |
| 2024 | 21.26% | -3.71% |
| 2023 | 22.08% | 2.89% |
| 2022 | 21.46% | 13.48% |
| 2021 | 18.91% | 6.66% |
| 2020 | 17.73% | -26.03% |
| 2019 | 23.97% | 0.67% |
| 2018 | 23.81% | -15.48% |
| 2017 | 28.17% | -15.33% |
| 2016 | 33.27% | 51.36% |
| 2015 | 21.98% | 8.49% |
| 2014 | 20.26% | -28.59% |
| 2013 | 28.37% | 31.46% |
| 2012 | 21.58% | 23.88% |
| 2011 | 17.42% | -34.98% |
| 2010 | 26.79% | 8.46% |
| 2009 | 24.70% | -7.49% |
| 2008 | 26.70% | -21.98% |
| 2007 | 34.22% | 5.72% |
| 2006 | 32.37% | 60.01% |
| 2005 | 20.23% | -20.07% |
| 2004 | 25.31% | 24.19% |
| 2003 | 20.38% | 3.19% |
| 2002 | 19.75% | -10.79% |
| 2001 | 22.14% | -1.29% |
| 2000 | 22.43% | 0.00% |
Marge opérationnelle pour des entreprises similaires ou concurrentes
| Entreprise | Marge opérationnelle | Différence de Marge Opérationnelle | Pays |
|---|---|---|---|
| 62.34% | -97.91% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 0.77% | -99.97% |
US
|
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.